These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12562682)

  • 1. HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity.
    Monini P; Sgadari C; Barillari G; Ensoli B
    J Antimicrob Chemother; 2003 Feb; 51(2):207-11. PubMed ID: 12562682
    [No Abstract]   [Full Text] [Related]  

  • 2. Scientific considerations for pharmacoenhancers in antiretroviral therapy.
    Arya V; Robertson SM; Struble KA; Murray JS
    J Clin Pharmacol; 2012 Aug; 52(8):1128-33. PubMed ID: 21712496
    [No Abstract]   [Full Text] [Related]  

  • 3. [HIV protease inhibitors for the treatment of Kaposi's sarcoma].
    Grosso G; Sgadari C; Barillari G; Toschi E; Bacigalupo I; Carlei D; Palladino C; Baccarini S; Malavasi L; Moracci G; Leone P; Chiozzini C; Monini P; Ensoli B
    Recenti Prog Med; 2003 Feb; 94(2):69-74. PubMed ID: 12908373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma.
    Sgadari C; Barillari G; Toschi E; Carlei D; Bacigalupo I; Baccarini S; Palladino C; Leone P; Bugarini R; Malavasi L; Cafaro A; Falchi M; Valdembri D; Rezza G; Bussolino F; Monini P; Ensoli B
    Nat Med; 2002 Mar; 8(3):225-32. PubMed ID: 11875492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma.
    Esposito V; Palescandolo E; Spugnini EP; Montesarchio V; De Luca A; Cardillo I; Cortese G; Baldi A; Chirianni A
    Clin Cancer Res; 2006 Apr; 12(8):2634-9. PubMed ID: 16638877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage therapy for patients failing their current antiretroviral regimen.
    Albrecht MA
    AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy.
    Morse GD; Catanzaro LM; Acosta EP
    Lancet Infect Dis; 2006 Apr; 6(4):215-25. PubMed ID: 16554246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different impact of anti-retroviral regimen containing protease inhibitors on development of HIV-related Kaposi sarcoma.
    Carleo MA; Di Martino F; Del Giudice A; Gargiulo M; Parrella G; Rosario P; Sangiovanni V; Viglietti R; Esposito V; Chirianni A
    In Vivo; 2015; 29(1):133-6. PubMed ID: 25600542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of protease inhibitors and the fight with drug-resistant HIV-1 variants.
    Mitsuya H; Maeda K; Das D; Ghosh AK
    Adv Pharmacol; 2008; 56():169-97. PubMed ID: 18086412
    [No Abstract]   [Full Text] [Related]  

  • 10. Hydroxyurea may enhance effectiveness of anti-HIV regimens presently in use.
    Murphy MJ
    Fac Notes (New Orleans La); 1998; 10(2):1-2. PubMed ID: 11365124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of HIV protease inhibitor resistance in treatment-naive populations in the united states.
    Hicks C
    AIDS Read; 2005 Dec; 15(12):683-6, 689-90. PubMed ID: 16355598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protease inhibitors: resistance, resistance, resistance.
    Gilden D; Falkenberg J; Torres G
    GMHC Treat Issues; 1997 Feb; 11(2):5-10. PubMed ID: 11364108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protease inhibitors.
    Treat Rev; 1995; (no 19):2. PubMed ID: 11362753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current knowledge and future prospects for the use of HIV protease inhibitors.
    Moyle G; Gazzard B
    Drugs; 1996 May; 51(5):701-12. PubMed ID: 8861542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 16. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies.
    Erickson JW; Gulnik SV; Markowitz M
    AIDS; 1999; 13 Suppl A():S189-204. PubMed ID: 10885776
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-HIV drugs for cancer therapeutics: back to the future?
    Chow WA; Jiang C; Guan M
    Lancet Oncol; 2009 Jan; 10(1):61-71. PubMed ID: 19111246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Human immunodeficiency virus and antiretroviral therapy resistance].
    Quirós E; Torti C; Carosi G
    Enferm Infecc Microbiol Clin; 2000 May; 18(5):234-7. PubMed ID: 10974768
    [No Abstract]   [Full Text] [Related]  

  • 19. The development of anti-HIV-1 drugs.
    Lu XF; Chen ZW
    Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of HIV-protease inhibitors on opportunistic parasites.
    Pozio E; Morales MA
    Trends Parasitol; 2005 Feb; 21(2):58-63. PubMed ID: 15664527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.